SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence, Challenges, and Opportunities for Cure.

The therapeutic landscape of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) has rapidly evolved over the past decade with the introduction of multiple novel agents and the emergence of immunotherapies such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. As these therapies become integrated into routine clinical practice, current treatment approaches now increasingly rely on timing of relapse and patient-specific factors such as eligibility and access to CAR T-cell therapy. Consequently, treatment sequencing has become increasingly complex and now represents a major challenge in the management of R/R DLBCL. In this review, we summarize the pivotal clinical trials that have informed current treatment strategies and discuss evolving approaches to sequencing therapies in R/R DLBCL, with an aim of optimizing curative potential.